Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Minocycline In Neurocognitive Outcomes - Sickle Cell Disease
NCT05605366Phase 1Not yet recruiting
- Sponsor
- University of Cincinnati
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of minocycline in sickle cell disease (SCD) and No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity (3 arms), sponsored by University of Cincinnati. Primary endpoint: Safety and tolerability of prolonged minocycline exposure at 12 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
minocycline
03
Conditions
sickle cell disease (SCD)No canonical disease name; "cognitive deterioration" is a descriptive term, not a recognized disease entity.
Beyond the preview
Go deeper on NCT05605366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05605366.